Disitamab Vedotin（RC48）combined with EGFR or HER2 TKIs in locally advanced or metastatic NSCLC Patients with HER2 Alterations.
Age: 18 (inclusive) or above, regardless of gender.
Histologically or cytologically confirmed locally advanced or metastatic NSCLC, not suitable for radical surgery or radiotherapy (TNM 8th Edition).".
HER2 alterations include HER2 gene mutations, gene amplification and HER2 protein over-expression;
Arm1: patients who have not previously received systemic treatment for advanced diseases;
Central nervous system metastasis or meningeal metastasis with clinical symptoms.
Known hypersensitivity or intolerance to any component of the study protocol drug or its excipients.
Have a history of severe cardiovascular disease.
Have a history of interstitial lung disease or drug-induced interstitial lung disease requiring steroids treatment; radiation pneumonia.